TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-03-06
徐志宏Hsu, Chih-Hung
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
33筆
21
Hung YP, Shao YY, Hsu C, Hsu CH, Lee JM, Yang MH, Chao Y. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. J Formos Med Assoc. 2021 Aug;120(8):1581-1590. doi: 10.1016/j.jfma.2020.11.015. Epub 2020 Dec 15. PMID: 33334658.
22
Shao YY, Lin WY, Lin CP, Lu LC, Hsu CH. Solving the deficit of cancer pain management skills by education programs. Support Care Cancer. 2021 Apr;29(4):1843-1848. doi: 10.1007/s00520-020-05651-2. Epub 2020 Aug 11. PMID: 32779009.
23
Kuo HY, Guo JC, Hsu CH. Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives. J Formos Med Assoc. 2020 Feb;119(2):565-568. doi: 10.1016/j.jfma.2019.10.010. Epub 2019 Oct 23. PMID: 31668650.
24
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12. PMID: 32161368; PMCID: PMC7188670.
25
Shao YY, Liu TH, Hsu C, Lu LC, Shen YC, Lin ZZ, Cheng AL, Hsu CH. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 2019 Nov;39(11):2184-2189. doi: 10.1111/liv.14210. Epub 2019 Aug 31. PMID: 31400295.
26
Huang TC, Lin CC, Wu YC, Chia-Hsien Cheng J, Lee JM, Wang HP, Huang PM, Hsu FM, Yeh KH, Cheng AL, Tzen KY, Hsu CH. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. J Formos Med Assoc. 2019 Jun;118(6):1024-1030. doi: 10.1016/j.jfma.2018.11.003. Epub 2018 Nov 28. PMID: 30502100.
27
Lu SL, Hsu FM, Tsai CL, Lee JM, Huang PM, Hsu CH, Lin CC, Chang YL, Hsieh MS, Cheng JC. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment. Eur J Surg Oncol. 2019 Aug;45(8):1498-1504. doi: 10.1016/j.ejso.2019.03.020. Epub 2019 Mar 19. PMID: 30910457.
28
Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, Hung YP, Chang CJ, Shen YC, Guo JC, Liu TH, Hsu CH, Cheng AL. Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer. 2019 Nov;8(6):480-490. doi: 10.1159/000501275. Epub 2019 Aug 6. PMID: 31799205; PMCID: PMC6883443.
29
Guo JC, Lin CC, Lin CY, Hsieh MS, Kuo HY, Lien MY, Shao YY, Huang TC, Hsu CH. Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Anticancer Res. 2019 Oct;39(10):5675-5682. doi: 10.21873/anticanres.13765. PMID: 31570466.
30
Shao YY, Li YS, Hsu HW, Lin H, Wang HY, Wo RR, Cheng AL, Hsu CH. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers (Basel). 2019 Sep 26;11(10):1433. doi: 10.3390/cancers11101433. PMID: 31561409; PMCID: PMC6827105.
